Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT

Bone Marrow Transplantation volume 42, pages S67–S70 (2008)Cite this article

Abstract

Pharmacokinetic studies of high-dose treosulfan were carried out in seven paediatric patients (age range: 2–15 years) undergoing treosulfan-based conditioning regimen prior to allogeneic haematopoietic SCT. Treosulfan was administered intravenously in a daily dose of 10, 12 or 14 g/m2 within 2 h. Five out of seven patients received 12 g/m2. The plasma concentrations of treosulfan and its quantity eliminated with urine were determined using a validated HPLC method with refractometric detection. Pharmacokinetic parameters were evaluated following first dose using a two-compartment disposition model. These studies demonstrated a dose-dependent increase of area under the concentration (AUC) and maximum concentrationplasma (Cmax), but there was variability of these parameters. Rapid clearance of tresoulfan was observed, especially in 10 and 12 g/m2 doses. Terminal half-life (t0.5) of treosulfan was in the range of 1.71–2.15 h, but the mean percent of parent drug eliminated with urine was 30%, range 16.3–45.4% of the total dose eliminated during the first 12 h after administration. The results of this study confirmed the linear pharmacokinetics of treosulfan, as used in children. However, variability of pharmacokinetic results observed in children studied demonstrates the need for pharmacokinetic evaluation in each paediatric patient undergoing the treosulfan-based preparative regimen, including those using different doses. This approach could enable further reduction of the risk of early and late organ toxicity related to high-dose treosulfan in paediatric patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Hartley JA, O’Hare CC, Baumgart J . DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer 1999; 79: 264–266.

    Article  CAS  Google Scholar 

  2. Boobis A, Rawlins M, Thomas S, Wilkins M . Treosulfan. In: Dollery C (ed). The Drugs. Churchill Livingstone: Edinburgh, 1999, pp 161–163.

    Google Scholar 

  3. Hilger RA, Harstrick A, Eberhardt W, Oberhoff C, Skorzec M, Baumgart J et al. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol 1998; 42: 99–104.

    Article  CAS  Google Scholar 

  4. Hilger RA, Jacek G, Oberhoff C, Kredtke S, Baumgart J, Seeber S et al. Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer. Cancer Chemother Pharmacol 2000; 45: 483–488.

    Article  CAS  Google Scholar 

  5. Hilger RA, Baumgart J, Scheulen ME, Trenschel R, Strumberg D, Seeber S et al. Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic cell transplantation. Intern J Clin Pharmacol Ther 2004; 42: 654–655.

    Article  CAS  Google Scholar 

  6. Werner S, Mendoza A, Hilger RA, Erlacher M, Reichardt W, Lissat A et al. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma. Cancer Chemother Pharmacol 2008; 62: 19–31.

    Article  CAS  Google Scholar 

  7. Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogenic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 2005; 35: 233–241.

    Article  CAS  Google Scholar 

  8. Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 2000; 6: 4209–4216.

    CAS  PubMed  Google Scholar 

  9. Markiewicz M, Wojciechowska M, Wyleżoł I, Woźniczka K, Giebel S, Wojnar J et al. Unrelated bone marrow transplantation with treosulfan-based myeloablative conditioning for paroxysmal nocturnal hemoglobinuria—successful treatment despite multiple transplant related risk factors for hemolysis including major Kidd group incompatibility. Bone Marrow Transplant 2006; 37: 231–232.

    Article  CAS  Google Scholar 

  10. Wachowiak J, Chybicka A, Kowalczyk J, Boruczkowski D, Górczyńska A, Wójcik B et al. Retrospective study on treosulfan-based preparative regimen for allogenic HSCT in children with hematological malignancies and high risk of conventional regimen related toxicity. Bone Marrow Transplant 2005; 35 (S2): 261.

    Google Scholar 

  11. Główka FK, Karaźniewicz-Łada M, Grund G, Wachowiak J . Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation. J Chromatogr B 2007; 850: 569–574.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Medac GmbH from Hamburg for the kind supply of the refractometric detector.

Author information

Authors and Affiliations

  1. Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Poznań, Poland

    F K Główka, M Karaźniewicz-łada & T Wróbel

  2. Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, Poznań, Poland

    G Grund & J Wachowiak

Authors
  1. F K Główka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Karaźniewicz-łada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Grund
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Wróbel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Wachowiak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F K Główka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Główka, F., Karaźniewicz-łada, M., Grund, G. et al. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT. Bone Marrow Transplant 42 (Suppl 2), S67–S70 (2008). https://doi.org/10.1038/bmt.2008.287

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.287

Keywords

Search

Advanced search

Quick links